Prostate Cancer
"Apples and Oranges: Building a Consensus for Standardized Eligibility Criteria and End Points in Prostate Cancer Clinical Trials."
Published in Cancer Weekly, November 30th, 1998
According to the author's abstract of an article published in Journal of Clinical Oncology, "Purpose: To survey eligibility and response criteria for clinical trials in hormone refractory prostate cancer (HRPC). Methods: Thirty-five established investigators of HRPC completed a 125-question survey Results: There was a general consensus that criteria total trial entry would include progression based on an increasing prostate-specific antigen (PSA) level (94% of investigators), an increase in measurable disease (91%), and/or appearance of new bone lesions on bone scan (83%). Most believed that castrate levels of testosterone (77%) and progression after...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (1998-11-30)
More Articles from Cancer Weekly
- Cancer Gene Therapy
Oral DNA Vaccination Provides Antitumor Immunity - Cancer Gene Therapy
Gene Expression Determines Retinoid Sensitivity - Cancer Immunotherapy
Flt3 Ligand Helps Generate Dendritic Cells for Therapy - Cancer Immunotherapy
IL-15 Activates Tumor-Specific Gamma Delta T Cells - Cancer Immunotherapy
Intralesional Cytokine Delivery Causes Systemic Toxicity - Cancer Immunotherapy
New Melanoma Antigen Discovered - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
